Itraconazole, Cytochrome p450 inhibitor (ab120816)
Key features and details
- Cytochrome p450 inhibitor
- CAS Number: 84625-61-6
- Purity: > 99%
- Soluble in DMSO to 50 mM and in ethanol to 10 mM (with warming)
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Itraconazole, Cytochrome p450 inhibitor -
製品の詳細
Cytochrome p450 inhibitor -
別名
- Oriconazole
- R 51211
-
精製度
> 99% -
CAS 番号
84625-61-6 -
構造式
製品の特性
-
体系名
4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one -
分子量
705.64 -
分子式
C35H38Cl2N8O4 -
保存方法
Store at -20°C. It is important to note that this product is reported to be light sensitive. Store In the Dark. Store under desiccating conditions. -
溶解性
Soluble in DMSO to 50 mM and in ethanol to 10 mM (with warming) -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120816の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab120816, Itraconazole, Cytochrome p450 inhibitor
-
HepG2 cells were incubated at 37°C for 24h with vehicle control (0 µM) and different concentrations of itraconazole (ab120816). Increased expression of cytochrome P450 1A1 (ab3568) in HepG2 cells correlates with an increase in nifuroxazide concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab3568 at 1/500 dilution and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (0)
ab120816 は論文での使用が確認できていません。